These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 10688391

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR, Nicolau DP, Onyeji CO, Nightingale CH.
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM, Kang SL, Palmer SM, Rybak MJ.
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model.
    Cappelletty DM.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):129-33. PubMed ID: 9869577
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS, Summers KK, Hardin TC.
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [Abstract] [Full Text] [Related]

  • 9. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers.
    Hollenstein U, Brunner M, Mayer BX, Delacher S, Erovic B, Eichler HG, Müller M.
    Clin Pharmacol Ther; 2000 Mar; 67(3):229-36. PubMed ID: 10741625
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
    Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, Chabanon G, Virenque C, Houin G, Saivin S.
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):360-9. PubMed ID: 16119511
    [Abstract] [Full Text] [Related]

  • 14. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [Abstract] [Full Text] [Related]

  • 15. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC, Shea KM, Healy DP, Humphrey ML, Fleming MR, Wack MF, Smith DW, Sowinski KM, Kays MB.
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Huang V, Rybak MJ.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):302-8. PubMed ID: 15616309
    [Abstract] [Full Text] [Related]

  • 18. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
    Klepser ME, Patel KB, Nicolau DP, Quintiliani R, Nightingale CH.
    Pharmacotherapy; 1998 Jan; 18(5):1069-74. PubMed ID: 9758317
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.
    Crandon JL, Bulik CC, Kuti JL, Nicolau DP.
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1111-6. PubMed ID: 20038614
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.